UCSF Benioff Children’s Hospital Oakland is enrolling patients in an innovative clinical trial that seeks to cure sickle cell disease. The trial is the first in the U.S. to apply non-viral CRISPR-Cas9 ...

In November 2023, the UK became the first country in the world to authorise a Crispr gene-editing therapy.

SAN DIEGO — A newly approved gene therapy product for sickle cell disease, lovotibeglogene autotemcel (lovo-cel, marketed as Lyfgenia), led to durable disease remissions for up to 5 years and almost ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

When Dr. Ambroise Wonkam walked into a panel on medical genetics out of curiosity, he had no idea it would shape the course of his career. Born in Cameroon, Wonkam has dedicated his career to studying ...

The U.S. Patent and Trademark Office has accepted a groundbreaking patent from Dei BioPharma Ltd., marking a significant milestone in the treatment of sickle cell disease.Dei BioPharma, a Ugandan ...

Gene editing has moved from theory to bedside with a speed that would have seemed impossible a decade ago. A new wave of CRISPR advances is not only correcting single mutations in the lab but ...

NHS Scotland has approved a one-time CRISPR gene therapy for severe sickle cell disease, offering durable reduction in vaso-occlusive crises for eligible patients.

Sickle cell disease is caused by a mutation in the gene that produces hemoglobin, which results in red blood cells becoming stiff, sticky, and shaped like a sickle. [Courtesy]. In Kisumu, Kenya’s ...